Furiex

Morrisville, United States Founded: 2009 • Age: 17 yrs Listed Acquired By Actavis
Drug development for gastroenterology disorders is conducted.

About Furiex

Furiex is a Healthcare company based in Morrisville (United States) founded in 2009, and was acquired by Actavis in April 2014. Drug development for gastroenterology disorders is conducted. Furiex offers products and services including RINVOQ and TrenibotulinumtoxinE. Its focus areas include Life Sciences, Gastroenterology, Drugs and Diversified. Its legal entity is Furiex Pharmaceuticals, Inc. Its competitors include Ironwood Pharma, Ardelyx and Alcresta; 3 of its 3 listed competitors have raised funding.

Company details

Furiex Pharmaceuticals was established in 2009 in Morrisville, United States, within the pharmaceutical sector. Focus was placed on developing eluxadoline, a mu opioid receptor agonist and delta opioid receptor antagonist, targeted at diarrhea-predominant irritable bowel syndrome. Two Phase III clinical trials were completed in 2014, meeting primary endpoints for stool consistency and abdominal pain improvements as agreed with FDA and EMA. Acquisition by Actavis occurred in 2014.

Operational Areas
Key Metrics

Products & Services of Furiex

Furiex offers a comprehensive portfolio of products and services, including RINVOQ and TrenibotulinumtoxinE.

RINVOQ
Immunology Drug

Treats adults with giant cell arteritis and other inflammatory conditions.

TrenibotulinumtoxinE
Neurology Drug

Addresses glabellar lines with rapid onset action.

Apps and channels of Furiex

its YouTube channel AbbVie has 56 subscribers and 30 videos.

AbbVie
YouTube 56 subscribers 30 videos Science & Technology
Open channel

Videos from Furiex

The most watched videos on Furiex's YouTube channel, AbbVie (56 subscribers). Click a video to play it here.

Make a Difference Working at AbbVie
5.4K views
How AbbVie Uses Technology to Accelerate Drug Development for Patients
3.6K views
AbbVie Employees Share Their Stories Living with Migraine
2.5K views
Internships at AbbVie
2.3K views

More on AbbVie.

Investors in Furiex

Furiex has secured backing from 1 investor. Prominent investors backing the company include Actavis.

All
InvestorDescriptionFounded YearDomainLocation
Manufacturer of generic products
1956actavis.comParsippany Troy Hills, United States
Premium access

Investor details for Furiex

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Furiex

3 dated milestones of Furiex across 5 years, from founding to its latest funding, stage changes and deals.

  1. Founded Furiex is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Exit Acquired by Actavis.

Competitors of Furiex

Furiex has 3 listed competitors in our database, 3 of them funded. They include Ironwood Pharma, Ardelyx and Alcresta.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
ironwoodpharma.com1998Cambridge, United States$206.25M220
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
ardelyx.com2007Fremont, United States$61.1M37
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
alcresta.com2011Newton, United States$95.89M52
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
Premium access

Detailed competitors of Furiex

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Gastroenterology

3 companies that operate in the same segment as Furiex (Gastroenterology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
1998Cambridge, Massachusetts, United StatesUSD 206.25 MUSD 296.15 M253
Sacral neuromodulation devices are developed for urinary and bowel control.
2013Irvine, California, United StatesUSD 143.47 M
Provider of a deep learning platform for detecting circulating cancer-related markers
2014United StatesUSD 1.35 B411
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Furiex

Furiex was founded in 2009.

Furiex is headquartered in Morrisville, United States.

Furiex Pharmaceuticals was established in 2009 in Morrisville, United States, within the pharmaceutical sector. Focus was placed on developing eluxadoline, a mu opioid receptor agonist and delta opioid receptor antagonist, targeted at diarrhea-predominant irritable bowel syndrome. Two Phase III clinical trials were completed in 2014, meeting primary endpoints for stool consistency and abdominal pain improvements as agreed with FDA and EMA. Acquisition by Actavis occurred in 2014.

Furiex's top competitors include Ironwood Pharma, Ardelyx and Alcresta.

Furiex offers RINVOQ and TrenibotulinumtoxinE.

Furiex has 1 investor. Key investors include Actavis.

Furiex operates through Furiex Pharmaceuticals, Inc.

Yes. Furiex was acquired by Actavis in April 2014.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available